OnCo
Start hereTagsgallbladder-deep-dive

gallbladder-deep-dive

All tags →

Registry-only phase 2 and 3 trials that name gallbladder cancer in their conditions or eligibility, recorded from ClinicalTrials.gov during the gallbladder cancer deep dive. 131 records carry it: 131 trials.

131 records
A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
NCT07632235
A phase 1/2 trial of pembrolizumab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Shanghai 6th People's Hospital, not yet recruiting.
A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.
NCT07729033
A phase 2 trial of sacituzumab tirumotecan and envafolimab in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.
A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.
NCT07679399
A phase 2 trial of durvalumab, capecitabine, gemcitabine and other drugs in gallbladder cancer and other biliary tract cancers, run by Peking Union Medical College Hospital, now recruiting.
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
NCT07623642
A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by GV20 Therapeutics, not yet recruiting.
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
NCT06728410
A phase 2 trial of durvalumab and pemigatinib in gallbladder cancer and other biliary tract cancers, run by Mehmet Akce, now recruiting.
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers
NCT07351591
A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by Eastern Hepatobiliary Surgery Hospital, not yet recruiting.
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
NCT07269158
A phase 1/2 trial of durvalumab, pembrolizumab and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Yonsei University, not yet recruiting.
A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)
NCT07471165
A phase 2 trial of the registered interventions with radiotherapy in gallbladder cancer and other biliary tract cancers, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.
A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen
NCT07099794
A phase 2 trial of fluorouracil, liposomal irinotecan and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting.
A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs
NCT06423170
A phase 2 trial of camrelizumab, gemcitabine and oxaliplatin in gallbladder cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting.
A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer
NCT07135544
A phase 2 trial of adebrelimab in gallbladder cancer and other biliary tract cancers, run by Yongjun Chen, now recruiting.
A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.
NCT06654947
A phase 2 trial of toripalimab, gemcitabine, oxaliplatin and surufatinib in gallbladder cancer and other biliary tract cancers, run by Fujian Cancer Hospital, not yet recruiting.
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
NCT05849480
A phase 1/2 trial of oxaliplatin, capecitabine and CAPOX in gallbladder cancer and other biliary tract cancers, run by National Cancer Institute (NCI), now recruiting.
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
NCT02151084
A phase 2 trial of gemcitabine, cisplatin and selumetinib in gallbladder cancer and other biliary tract cancers, run by University Health Network, Toronto, active and no longer recruiting.
A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.
NCT06620848
A phase 2 trial of adebrelimab in gallbladder cancer and other biliary tract cancers, run by Shanghai Zhongshan Hospital, now recruiting.
A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer
NCT02632305
A phase 2 trial of gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by AHS Cancer Control Alberta, active and no longer recruiting.
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
NCT07392541
A phase 1/2 trial of adebrelimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Tongji Hospital, now recruiting.
Adebrelimab Plus S-1 for Resected Cholangiocarcinoma
NCT07561775
A phase 2 trial of adebrelimab and S-1 in gallbladder cancer and other biliary tract cancers, run by Xingjun Guo, not yet recruiting.
Adjuvant Chemotherapy for BTC Based on 3D-PTA
NCT07296666
A phase 2 trial of capecitabine in gallbladder cancer and other biliary tract cancers, run by Fudan University, not yet recruiting.
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
NCT03801083
A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by Udai Kammula, active and no longer recruiting.
Agnostic Therapy in Rare Solid Tumors
NCT06638931
A phase 2 trial of nivolumab in gallbladder cancer and other biliary tract cancers, run by Instituto do Cancer do Estado de São Paulo, now recruiting.
AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer
NCT07767994
A phase 2 trial of ivonescimab, gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by First Affiliated Hospital Xi'an Jiaotong University, not yet recruiting.
Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
NCT07780838
A phase 2 trial of durvalumab, gemcitabine, cisplatin and pemigatinib in gallbladder cancer and other biliary tract cancers, run by Ohio State University Comprehensive Cancer Center, now recruiting.
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
NCT07569679
A phase 2 trial of adebrelimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Air Force Military Medical University, China, now recruiting.
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
NCT07282262
A phase 2 trial of lenvatinib and ivosidenib in gallbladder cancer and other biliary tract cancers, run by Peking Union Medical College Hospital, now recruiting.
An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies
NCT07668453
A phase 2 trial of adebrelimab, gemcitabine and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by The First Affiliated Hospital with Nanjing Medical University, now recruiting.
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
NCT06662877
A phase 2/3 trial of oxaliplatin, fluorouracil, leucovorin and other drugs in gallbladder cancer and other biliary tract cancers, run by Sun Yat-sen University, not yet recruiting.
Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer
NCT07635290
A phase 2 trial of cadonilimab and anlotinib in gallbladder cancer and other biliary tract cancers, run by West China Hospital, active and no longer recruiting.
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
NCT05000294
A phase 1/2 trial of atezolizumab and tivozanib in gallbladder cancer, run by University of Florida, now recruiting.
Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II
NCT07649980
A phase 2 trial of pucotenlimab in gallbladder cancer and other biliary tract cancers, run by HuiKai Li, not yet recruiting.
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
NCT07594626
A phase 1/2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by Northwestern University, now recruiting.
Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
NCT06438822
A phase 2 trial of cadonilimab, fluorouracil, leucovorin and liposomal irinotecan in gallbladder cancer and other biliary tract cancers, run by West China Hospital, now recruiting.
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
NCT06901622
A phase 2 trial of camrelizumab, nab-paclitaxel, S-1 and anlotinib in gallbladder cancer and other biliary tract cancers, run by The First Affiliated Hospital of Zhengzhou University, now recruiting.
Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
NCT05451290
A phase 2 trial of camrelizumab, gemcitabine, oxaliplatin and S-1 in gallbladder cancer and other biliary tract cancers, run by First Affiliated Hospital of Zhejiang University, active and no longer recruiting.
Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody
NCT05994001
A phase 1/2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by Shanghai Zhongshan Hospital, active and no longer recruiting.
Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
NCT06280508
A phase 2 trial of adebrelimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting.
Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
NCT06037655
A phase 2 trial of adebrelimab in gallbladder cancer and other biliary tract cancers, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma
NCT07570849
A phase 2 trial of gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Shanghai Zhongshan Hospital, now recruiting.
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
NCT06037980
A phase 2/3 trial of gemcitabine, cisplatin, capecitabine and paclitaxel in gallbladder cancer and other biliary tract cancers, run by Gruppo Oncologico del Nord-Ovest, now recruiting.
Combination Immunotherapy in Rare Cancers Under InvesTigation
NCT04969887
A phase 2 trial of nivolumab and ipilimumab in gallbladder cancer and other biliary tract cancers, run by Olivia Newton-John Cancer Research Institute, active and no longer recruiting.
Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
NCT05757336
A phase 2 trial of sintilimab, gemcitabine, nab-paclitaxel and bevacizumab in gallbladder cancer, run by Lu Wang, MD, PhD, now recruiting.
Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer
NCT07151872
A phase 2 trial of gemcitabine, cisplatin, oxaliplatin and capecitabine in gallbladder cancer and other biliary tract cancers, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
NCT03937830
A phase 2 trial of durvalumab, tremelimumab and bevacizumab in gallbladder cancer and other biliary tract cancers, run by National Cancer Institute (NCI), active and no longer recruiting.
Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)
NCT06502080
A phase 2 trial of durvalumab, pembrolizumab, sintilimab and other drugs with radiotherapy in gallbladder cancer and other biliary tract cancers, run by Shanghai Zhongshan Hospital, not yet recruiting.
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
NCT05733000
A phase 2 trial of gemcitabine and fluorouracil in gallbladder cancer and other biliary tract cancers, run by Northwestern University, now recruiting.
Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.
NCT07829874
A phase 2 trial of lenvatinib in gallbladder cancer and other biliary tract cancers, run by Fudan University, not yet recruiting.
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
NCT06548412
A phase 1/2 trial of durvalumab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by M.D. Anderson Cancer Center, now recruiting.
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
NCT07159217
A phase 2 trial of disitamab vedotin, pembrolizumab, camrelizumab and other drugs in gallbladder cancer and other biliary tract cancers, run by Peking Union Medical College Hospital, not yet recruiting.
Domvanalimab and Zimberelimab in Advanced Liver Cancers
NCT05724563
A phase 2 trial of zimberelimab and domvanalimab in gallbladder cancer and other biliary tract cancers, run by University of Texas Southwestern Medical Center, active and no longer recruiting.
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
NCT03482102
A phase 2 trial of durvalumab and tremelimumab with radiotherapy in gallbladder cancer and other biliary tract cancers, run by Massachusetts General Hospital, active and no longer recruiting.
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
NCT05451043
A phase 2 trial of durvalumab, tremelimumab, gemcitabine and other drugs in gallbladder cancer and other biliary tract cancers, run by AHS Cancer Control Alberta, now recruiting.
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
NCT05640791
A phase 2 trial of durvalumab, gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.
Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
NCT06490107
A phase 2 trial of durvalumab and S-1 in gallbladder cancer and other biliary tract cancers, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, active and no longer recruiting.
Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study
NCT07636824
A phase 2 trial of capecitabine and S-1 with radiotherapy in gallbladder cancer and other biliary tract cancers, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.
Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer
NCT07638501
A phase 2 trial of sintilimab, gemcitabine and cisplatin with radiotherapy in gallbladder cancer and other biliary tract cancers, run by Eastern Hepatobiliary Surgery Hospital, not yet recruiting.
Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
NCT07003815
A phase 2 trial of envafolimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Tongji Hospital, not yet recruiting.
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
NCT04645160
A phase 1/2 trial of tivozanib in gallbladder cancer and other biliary tract cancers, run by National Cancer Institute (NCI), now recruiting.
Evaluating Novel Therapies in ctDNA Positive GI Cancers
NCT05482516
A phase 3 trial of atezolizumab and bevacizumab in gallbladder cancer and other biliary tract cancers, run by Georgetown University, now recruiting.
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
NCT07631884
A phase 2 trial of trastuzumab rezetecan in gallbladder cancer and other biliary tract cancers, run by Haihua Yuan, not yet recruiting.
Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma
NCT07105852
A phase 2 trial of sacituzumab tirumotecan and pucotenlimab in gallbladder cancer and other biliary tract cancers, run by Sir Run Run Shaw Hospital, now recruiting.
(showing the first 60)

The table above loads 60 of 131 records first and fetches the rest as you scroll, search or filter. This tag as JSON · table rows · API